Business Context and Reporting Period
CAMTEK LTD., a designer and manufacturer of intelligent optical inspection systems for the printed circuit board and microelectronics industries, reported consolidated financial results for the quarter ended March 31, 2003. The filing is a Form 6-K dated May 19, 2003, incorporating a press release issued on May 15, 2003.
Key Financial Metrics
- Revenue: $5.8 million for Q1 2003.
- Gross Profit Margin: 39.7% (up from 37.1% in Q1 2002 and 33.9% in Q4 2002).
- Operating Expenses: Selling, general, and administrative (SG&A) expenses were $2.0 million; Research and development (R&D) costs were $1.6 million.
- Net Loss: $1.3 million, or $(0.05) per share (basic and diluted).
- Liquidity: Cash and cash equivalents increased to $14.9 million (reported as a net cash reserve of $14.2 million in the press release). Marketable securities were fully liquidated ($0).
- Working Capital: Accounts receivable decreased to $9.1 million; inventories decreased to $10.9 million.
- Debt: Short-term bank credit increased to $0.7 million; long-term loans were fully repaid ($0).
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 24% sequentially from $4.7 million in Q4 2002 and 25% year-over-year from $4.7 million in Q1 2002.
- Profitability Improvement: The net loss narrowed significantly to $1.3 million compared to $3.1 million in Q1 2002 and $3.4 million in Q4 2002. Loss per share improved from $(0.14) to $(0.05).
- Expense Reduction: SG&A expenses dropped to $2.0 million from $3.0 million in Q1 2002 and $2.7 million in Q4 2002. R&D costs decreased to $1.6 million from $2.0 million in Q1 2002.
- Balance Sheet Strength: Cash reserves grew substantially from $2.9 million at year-end 2002 to $14.9 million at March 31, 2003, driven by the liquidation of marketable securities and improved cash flow.
Guidance, Outlook, and Risks
- Guidance: Management estimates Q2 2003 revenues will range between $5 million and $7 million, citing flat overall demand with a slight increase in Asia.
- Management Commentary: CEO Rafi Amit stated results met guidance and expectations. Cost control measures are progressing toward break-even. The company recently launched the "Dragon," a fully automated AOI system, and plans new microelectronics products.
- Risks and Contingencies:
- SARS Epidemic: Management is monitoring the SARS outbreak but reported no current impact on customer purchasing or operations.
- Regulatory: The Israeli Securities Authority requires disclosure under Chapter F of the Securities Law following the company's transfer to the Nasdaq SmallCap Market. Camtek believes it should report under Chapter E3 and is considering legal action or delisting from the Tel Aviv Stock Exchange.
Investor Verification Checklist
- Verify the sustainability of the 24% sequential revenue growth given the "flat level of demand" cited by management.
- Confirm the timeline and market adoption rates for the new "Dragon" AOI system and upcoming microelectronics products.
- Monitor the resolution of the regulatory dispute with the Israeli Securities Authority regarding disclosure requirements.
- Assess the impact of the SARS epidemic on Asian manufacturing customers in subsequent quarters.
- Review the company's path to profitability given the continued net loss, despite improved margins and reduced expenses.